잠시만 기다려 주세요. 로딩중입니다.

폐경 후 골다공증 및 골감소증 여성의 denosumab 약물 사용 평가

Medication Use Evaluation of Denosumab in Postmenopausal Women with Osteoporosis or Osteopenia

한국임상약학회지 2020년 30권 3호 p.196 ~ 205
임선혜, 정우진, 채정우, 강찬, 윤휘열,
소속 상세정보
임선혜 ( Lim Seon-Hye ) - Chungnam National University Hospital Department of Pharmacy
정우진 ( Jung Woo-Jin ) - Chungnam National University College of Pharmacy
채정우 ( Chae Jung-Woo ) - Chungnam National University College of Pharmacy
강찬 ( Kang Chan ) - Chungnam National University Hospital Department of Orthopaedic Surgery
윤휘열 ( Yun Hwi-Yeol ) - Chungnam National University College of Pharmacy

Abstract


Background: The indication of denosumab for osteoporosis was expanded from second-line to first-line therapy in 2019. The aim of this study was to evaluate the efficacy of denosumab as both first- and second-line therapy in postmenopausal women with osteoporosis and osteopenia with risk factors by using the Fracture Risk Assessment Tool (FRAX).

Methods: We conducted a medication use evaluation of denosumab in 98 patients who had been treated three or more times for osteoporosis or osteopenia at Chungnam National University Hospital from July 1st, 2017 to January 31st, 2020. Risk factors were identified using quantitative Ngram analyses of FRAX estimations. Patient information, including menopause status and results of bone mineral density tests (Tscore), was obtained from electronic medical records.
Results: Age, body mass index (BMI), prior medication use, and T-score were identified as risk factors and were included as variables in the evaluation of denosumab use. Since no significant differences were detected between groups, denosumab is likely effective regardless of age or BMI. In addition, no significant difference was detected in T-scores following denosumab treatment, between groups who took bisphosphonates and selective estrogen receptor modulators (SERMs) with denosumab as first-line therapy for postmenopausal osteoporosis. Denosumab may, therefore, be effective as second-line therapy.

Conclusion: Efficacy of denosumab was evaluated in postmenopausal women with osteoporosis. Denosumab may be used as first- and second-line therapy regardless of age, BMI, and prior use of bisphosphonates and SERMs.

키워드

Denosumab; osteoporosis; osteopenia; medication use evaluation

원문 및 링크아웃 정보

 

등재저널 정보